IL17A and metabolic dysfunction-associated steatotic liver disease: Additionally, the positive correlations identified between IL-17 and other metabolic markers, such as triglycerides and insulin levels, support the idea that IL-17 is a key player in the metabolic dysfunction associated with MASLD [29].